Medical suppression of hypercortisolemia in Cushing's syndrome with particular consideration of etomidate

Pituitary

Volumn 15, Issue 2, 2012, Pages 117-125

  Heyn, Jens ^a   Geiger, Carolin ^b   Hinske, Christian L ^a   Briegel, Josef ^a   Weis, Florian ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b KLINIKUM BOGENHAUSEN   (Germany)

Author keywords

Adrenal suppression; Cushing syndrome; Etomidate; Hypercortisolemia

Indexed keywords

AMINOGLUTETHIMIDE; CORTICOTROPIN; CYPROHEPTADINE; ETOMIDATE; FLUCONAZOLE; GONADORELIN ANTAGONIST; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; MITOTANE; OCTREOTIDE; PASIREOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROPRANOLOL; VALPROIC ACID;

ADRENAL SUPPRESSION; ADRENALECTOMY; ANAPHYLAXIS; ANOREXIA; ATAXIA; BONE MARROW SUPPRESSION; CHOLESTASIS; CONFUSION; CONTINUOUS INFUSION; CORTICOTROPIN BLOOD LEVEL; CUSHING SYNDROME; DEXAMETHASONE SUPPRESSION TEST; DIARRHEA; DIZZINESS; DRUG DEGRADATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; EDEMA; FATIGUE; GYNECOMASTIA; HEART INDEX; HEART RATE; HIRSUTISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCHOLESTEROLEMIA; HYPERCORTISOLISM; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOPHYSIS TUMOR; HYPOTHYROIDISM; INJECTION SITE PAIN; LANGUAGE DISABILITY; LETHARGY; LIVER TOXICITY; MEAN ARTERIAL PRESSURE; MEMORY; MYOCLONUS; NAUSEA; OLIGURIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STEROIDOGENESIS; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; TORSADE DES POINTES; TRANSSPHENOIDAL SURGERY; VERTIGO; VOMITING;

ADRENAL GLANDS; ANIMALS; CUSHING SYNDROME; ETOMIDATE; HUMANS; HYDROCORTISONE;

EID: 84861462177     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-011-0314-3     Document Type: Review

References (68)

1. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C et al (2001) Incidence and late prognosis of cushing's syndrome: A population-based study. J Clin Endocrinol Metab 86:117-123 (Pubitemid 32111743)
2. Schteingart DE (2009) Drugs in the medical treatment of cushing's syndrome. Expert Opin Emerg Drugs 14:661-671
3. Lutgers HL, Vergragt J, Dong PV, de Vries J, Dullaart RP, van den Berg G et al (2010) Severe hypercortisolism: A medical emergency requiring urgent intervention. Crit Care Med 38:1598-1601
4. Ross EJ, Linch DC (1982) Cushing's syndrome-killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 320:646-649
5. Sarlis NJ, Chanock SJ, Nieman LK (2000) Cortisolemic indices predict severe infections in cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab 85:42-47 (Pubitemid 32268787)
6. Watson RG, van Heerden JA, Northcutt RC, Grant CS, Ilstrup DM (1986) Results of adrenal surgery for cushing's syndrome: 10 years0 experience. World J Surg 10:531-538 (Pubitemid 16096408)
7. Takagi S, Tanabe A, Tsuiki M, Naruse M, Takano K (2009) Hypokalemia, diabetes mellitus, and hypercortisolemia are the major contributing factors to cardiac dysfunction in adrenal cushing's syndrome. Endocr J 56:1009-1018
8. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM et al (2008) The diagnosis of Cushing's syndrome: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:1526-1540 (Pubitemid 351656485)
9. Newell-Price J (2009) Diagnosis/differential diagnosis of cushing's syndrome: A review of best practice. Best Pract Res Clin Endocrinol Metab 23(Suppl 1):S5-S14
10. Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing's syndrome. Lancet 367:1605-1617 (Pubitemid 43674231)
11. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D (2001) Successful long-Term treatment of refractory cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 86:3568-3573 (Pubitemid 32755945)
12. Mettauer N, Brierley J (2009) A novel use of etomidate for intentional adrenal suppression to control severe hypercortisolemia in childhood. Pediatr Crit Care Med 10:e37-e40
13. Gross BA, Mindea SA, Pick AJ, Chandler JP, Batjer HH (2007) Medical management of cushing disease. Neurosurg Focus 23:E10
14. Porterfield JR, Thompson GB, Young WF Jr. et al (2008) Surgery for cushing's syndrome: An historical review and recent ten-year experience. World J Surg 32:659-677
15. Thompson SK, Hayman AV, Ludlam WH, Deveney CW, Loriaux DL, Sheppard BC (2007) Improved quality of life after bilateral laparoscopic adrenalectomy for cushing's disease: A 10-year experience. Ann Surg 245:790-794 (Pubitemid 46684110)
16. Malley D, Boris R, Kaul S et al (2008) Synchronous bilateral adrenalectomy for adrenocorticotropic-dependent cushing's syndrome. J Soc Laparoendosc Surg 12:198-201
17. Assié G, Antoni G, Tissier F et al (2007) Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 92:148-154 (Pubitemid 46067523)
18. Markoe AM, Serber W, Micaily B et al (1991) Radiation therapy for adjunctive treatment of adrenal cortical carcinoma. Am J Clin Oncol 14:170-174
19. Fassnacht M, Hahner S, Polat B et al (2006) Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 91:4501-4504 (Pubitemid 44833430)
20. Abraham J, Bakke S, Rutt A et al (2002) A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94:2333-2343 (Pubitemid 34457113)
21. Williamson SK, Lew D, Miller GJ et al (2000) PhaseII evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: A southwest oncology group study. Cancer 88:1159-1165 (Pubitemid 30127678)
22. Feelders RA, Hofland LJ, de Herder WW (2010) Medical treatment of cushing's syndrome: Adrenal-blocking drugs and ketaconazole. Neuroendocrinology 92:111-115
23. Engelhardt D, Weber MM (1994) Therapy of cushing's syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol 49:261-267 (Pubitemid 24240610)
24. Nieman LK (2002) Medical therapy of cushing's disease. Pituitary 5:77-82 (Pubitemid 36336012)
25. Colao A, Pivonello R, Tripodi FS, Orio F Jr., Ferone D, Cerbone G et al (1997) Failure of long-Term therapy with sodium valproate in cushing's disease. J Endocrinol Invest 20:387-392
26. Krieger DT, Amorosa L, Linick F (1975) Cyproheptadineinduced remission of cushing's disease. N Engl J Med 293:893-896
27. Suri D, Weiss RE (2005) Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in cushing's disease. J Clin Endocrinol Metab 90:1340-1346 (Pubitemid 40463985)
28. Mercado-Asis LB, Yanovski JA, Tracer HL, Chik CL, Cutler GB Jr. (1997) Acute effects of bromocriptine, cyproheptadine, and valproic acid on plasma adrenocorticotropin secretion in Nelson's syndrome. J Clin Endocrinol Metab 82:514-517 (Pubitemid 27068621)
29. de Bruin C, Pereira AM, Feelders RA, Romijn JA, Roelfsema F, Sprij-Mooij DM et al (2009) Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab 94:1118-1124
30. Kraus J, Woltje M, Schonwetter N, Hollt V (1998) Alternative promoter usage and tissue specific expression of the mouse somatostatin receptor 2 gene. FEBS Lett 428:165-170 (Pubitemid 28319678)
31. Bertagna X, Favrod-Coune C, Escourolle H, Beuzeboc P, Christoforov B, Girard F et al (1989) Suppression of ectopic adrenocorticotropin secretion by the long-Acting somatostatin analog octreotide. J Clin Endocrinol Metab 68:988-991 (Pubitemid 19127421)
32. Boerlin V, van der Hoek J, Beglinger C, Poon KW, Hartmann S, Dutreix C et al (2003) New insights on SOM230, a universal somatostatin receptor ligand. J Endocrinol Invest 26:14-16
33. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M et al (2005) The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152:645-654 (Pubitemid 40575811)
34. Dang CN, Trainer P (2007) Pharmacological management of Cushing's syndrome: An update. Arq Bras Endocrinol Metabol 51:1339-1348
35. Santen RJ, Misbin RI (1981) Aminoglutethimide: review of pharmacology and clinical use. Pharmacotherapy 1:95-120 (Pubitemid 12016086)
36. Misbin RI, Canary J, Willard D (1976) Aminoglutethimide in the treatment of cushing's syndrome. J Clin Pharmacol 16:645-651
37. Schteingart DE, Conn JW (1967) Effects of aminoglutethimide upon adrenal function and cortisol metabolism in Cushing's syndrome. J Clin Endocrinol Metab 27:1657-1666
38. Loose DS, Kan PB, Hirst MA, Marcus RA, Feldman D (1983) Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest 71:1495-1499 (Pubitemid 13098940)
39. Luton JP, Mahoudeau JA, Bouchard P, Thieblot P, Hautecouverture M, Simon D et al (1979) Treatment of Cushing's disease by O, p0DDD. Survey of 62 cases. N Engl J Med 300:459-464 (Pubitemid 9134790)
40. Schteingart DE, Tsao HS, Taylor CI, McKenzie A, Victoria R, Therrien BA (1980) Sustained remission of cushing's disease with mitotane and pituitary irradiation. Ann Intern Med 92:613-619 (Pubitemid 10107550)
41. Leiba S, Weinstein R, Shindel B, Lapidot M, Stern E, Levavi H et al (1989) The protracted effect of o, p0-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo. Ann Endocrinol (Paris) 50:49-53 (Pubitemid 19063120)
42. Lacroix A, Tremblay J, Rousseau G, Bouvier M, Hamet P (1997) Propranolol therapy for ectopic beta-Adrenergic receptors in adrenal cushing's syndrome. N Engl J Med 337:1429-1434 (Pubitemid 27497890)
43. Lacroix A, Hamet P, Boutin JM (1999) Leuprolide acetate therapy in luteinizing hormone-dependent cushing's syndrome. N Engl J Med 341:1577-1581
44. Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P et al (2009) Merits and pitfalls of mifepristone in cushing's syndrome. Eur J Endocrinol 160:1003-1010
45. Dabbagh A, Sa'adat N, Heidari Z (2009) Etomidate infusion in the critical care setting for suppressing the acute phase of cushing's syndrome. Anesth Analg 108:238-239
46. Greening JE, Brain CE, Perry LA, Mushtaq I, Sales Marques J, Grossman AB et al (2005) Efficient short-Term control of hypercortisolaemia by low-dose etomidate in severe paediatric cushing's disease. Horm Res 64:140-143 (Pubitemid 41507296)
47. Drake WM, Perry LA, Hinds CJ, Lowe DG, Reznek RH, Besser GM (1998) Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with cushing's syndrome and peritonitis. J Clin Endocrinol Metab 83:3542-3544 (Pubitemid 28500886)
48. Krakoff J, Koch CA, Calis KA, Alexander RH, Nieman LK (2001) Use of a parenteral propylene glycol-containing etomidate preparation for the long-Term management of ectopic cushing's syndrome. J Clin Endocrinol Metab 86:4104-4108 (Pubitemid 32848520)
49. Johnson TN, Canada TW (2007) Etomidate use for cushing's syndrome caused by an ectopic adrenocorticotropic hormoneproducing tumor. Ann Pharmacother 41:350-353 (Pubitemid 46340068)
50. Hadzija BW, Lubarsky DA (1995) Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. Am J Health Syst Pharm 52:997-999
51. Van Hamme MJ, Ghoneim MM, Ambre JJ (1978) Pharmacokinetics of etomidate, a new intravenous anesthetic. Anesthesiology 49:274-277 (Pubitemid 9032541)
52. Meuldermans WE, Heykants JJ (1976) The plasma protein binding and distribution of etomidate in dog, rat and human blood. Arch Int Pharmacodyn Ther 221:150-162
53. de Ruiter G, Popescu DT, de Boer AG, Smeekens JB, Breimer DD (1981) Pharmacokinetics of etomidate in surgical patients. Arch Int Pharmacodyn Ther 249:180-188 (Pubitemid 11137043)
54. Paris A, Philipp M, Tonner PH, Steinfath M, Lohse M, Scholz J et al (2003) Activation of alpha 2B-Adrenoceptors mediates the cardiovascular effects of etomidate. Anesthesiology 99:889-895 (Pubitemid 37186080)
55. Fry DE, Griffiths H (1984) The inhibition by etomidate of the 11 beta-hydroxylation of cortisol. Clin Endocrinol (Oxf) 20:625-629
56. Reddy RV, Moorthy SS, Dierdorf SF, Deitch RD Jr., Link L (1993) Excitatory effects and electroencephalographic correlation of etomidate, thiopental, methohexital, and propofol. Anesth Analg 77:1008-1011 (Pubitemid 23319801)
57. Wells JK (1985) Comparison of ICI 35868, etomidate and methohexitone for day-case anaesthesia. Br J Anaesth 57:732-735 (Pubitemid 15043160)
58. McCollum JS, Dundee JW (1986) Comparison of induction characteristics of four intravenous anaesthetic agents. Anaesthesia 41:995-1000 (Pubitemid 16033138)
59. Scheffer GJ, Ten Voorde BJ, Karemaker JM, Ros HH, de Lange JJ (1993) Effects of thiopentone, etomidate and propofol on beatto-beat cardiovascular signals in man. Anaesthesia 48:849-855 (Pubitemid 23295030)
60. Lundy JB, Slane ML, Frizzi JD (2007) Acute adrenal insufficiency after a single dose of etomidate. J Intensive Care Med 22:111-117 (Pubitemid 46548132)
61. Schulte HM, Benker G, Reinwein D, Sippell WG, Allolio B (1990) Infusion of low dose etomidate: correction of hypercortisolemia in patients with cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 70:1426-1430
62. Allolio B, Stuttmann R, Fischer H, Leonhard W, Winkelmann W (1983) Long-Term etomidate and adrenocortical suppression. Lancet 322:626 (Pubitemid 13051068)
63. Gärtner R, Albrecht M, Müller OA (1986) Effect of etomidate on hypercortisolism due to ectopic ACTH production. Lancet 1:275 (Pubitemid 16132884)
64. Allolio B, Schulte HM, Kaulen D, Reincke M, Jaursch-Hancke C, Winkelmann W (1988) Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in cushing's syndrome. Klin Wochenschr 66:361-364
65. Herrmann BL, Mitchell A, Saller B (2001) Transsphenoidal hypophysectomy of a patient with an ACTH-producing pituitary adenoma and an "empty sella" after pretreatment with etomidate. Dtsch Med Wochenschr 126:232-234 (Pubitemid 32204770)
66. Bilgin YM, van der Wiel HE, Fischer HR, De Herder WW (2007) Treatment of severe psychosis due to ectopic cushing's syndrome. J Endocrinol Invest 30:776-779 (Pubitemid 350238205)
67. Lamberts SW, Bons EG, Bruining HA, de Jong FH (1987) Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J Pharmacol Exp Ther 240:259-264 (Pubitemid 17235446)
68. Varga I, Rácz K, Kiss R et al (1993) Direct inhibitory effect of etomidate on corticosteroid secretion in human pathologic adrenocortical cells. Steroids 58:64-68